GlobeNewswire
-
Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies
02/04/2026 -
Nanox Signs Distribution Agreement with Integrity Medical Service, Inc. to Deploy Nanox.ARC Systems
02/04/2026 -
Curanex Expands Its Drug Development Pipeline to Include Cancer Cachexia, Representing a Multi-Billion-Dollar Market Opportunity and Important Step In The Company’s Evolution Into a Broader Therapeutics Development Company
02/04/2026 -
MDIC appoints Philips Chief Medical Officer Carla Goulart Peron as new board member
02/04/2026 -
Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium
02/04/2026 -
Picard Medical / SynCardia COO to Deliver Keynote at Venture Café Phoenix During Arizona Tech Week
02/04/2026 -
Calidi Biotherapeutics to Present New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026
02/04/2026 -
Catheter Precision Engages Strategic Advisor
02/04/2026 -
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/04/2026 -
Bionano Announces Publication from Johns Hopkins and MD Anderson Showing that OGM can Outperform Traditional Methods in Analysis of Multiple Myeloma
02/04/2026 -
Revolution Medicines Begins Treating Patients in Phase 3 RASolute 303 Trial Evaluating Daraxonrasib as First Line Treatment for Patients with Metastatic Pancreatic Cancer
02/04/2026 -
Emergent BioSolutions Participates in Upcoming International Preparedness Conferences
02/04/2026 -
Provectus Biopharmaceuticals Highlights Preclinical Evidence of PV-10-Mediated Immune Modulation in Burn Wound Healing; Porcine Study Demonstrates Shift Toward Pro-Regenerative Tissue Environment
02/04/2026 -
Burning Rock Announces Founder’s Purchase of Its ADSs
02/04/2026 -
Arch Biopartners Closes Non-Brokered Private Placement
02/04/2026 -
Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
02/04/2026 -
Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)
02/04/2026 -
Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
02/04/2026 -
MyGevity Announces Nationwide Launch of Integrated Health Data Platform
02/04/2026
Pages